# ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors

> **Open Intelligence Dossier** · First detected: 2026-11-03 13:40 UTC · Category: Health

## Executive Summary
Recent coverage examines the impact of SGLT2 inhibitors on elderly patients with chronic kidney disease.

## Intelligence Brief
Current reporting highlights new findings concerning the health outcomes of elderly patients diagnosed with chronic kidney disease who receive SGLT2 inhibitors. According to coverage from Medical Xpress, the American Society of Nephrology meeting serves as the primary venue for these discussions. Additional details from Medscape, DocWireNews, and the South Florida Times specify that these kidney drugs provide notable cardiorenal protection and are linked to extended survival rates, even among individuals who are past the age of eighty. Outlets such as Medscape focus specifically on how SGLT2 inhibitors benefit mortality rates and cognitive functions in older patient populations with chronic kidney disease. DocWireNews emphasizes the broad protective qualities these medications confer upon the cardiovascular and renal systems alike.


Meanwhile, the South Florida Times report zeroes in on the longevity aspect, noting that survival advantages persist into advanced age brackets. Medical Xpress frames the collective findings around the announcements emerging from the ASN gathering. The broader context provided by the reporting situates these findings within ongoing medical evaluations of treatment efficacy for geriatric demographics suffering from chronic kidney conditions. Chronic kidney disease frequently presents complex management challenges in older adults due to overlapping cardiovascular risks and cognitive concerns. The data presented at the ASN meeting addresses these clinical questions by examining whether modern pharmacological interventions remain advantageous and safe for older cohorts.


Future developments to monitor, based strictly on the available coverage, depend on further reporting from medical meetings and specialized healthcare publications. Coverage does not yet specify subsequent regulatory actions or specific clinical guideline updates. Observers will track whether additional findings emerge from the American Society of Nephrology sessions regarding the full scope of SGLT2 inhibitor impacts on cognition and long-term survival.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Medscape | SGLT2i Benefit Mortality, Cognition in Older CKD Patients | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRUpDeGdFS1JwVVpOQUxlaUFudWRmb0xHWlB0d05XYlF0TDYzeVdmNDRKeFh6MzlDQ3JwcDR2WmY0SXh0bWIzREZNY0diSi1jOUxwUzQ1MDZzSGF1U09Od2ROMXd2eTRZcExlX1QyVzJVNS02R19MVGJaZlVERmVBMjI3cnRiR255RHlkcE92eTd1SzRJS1hkSFR3WlA3S2gzdXh4Mlh3WVJZQmM?oc=5) |
| DocWireNews | SGLT2 Inhibitors Confer Cardiorenal Protection - Metabolic Care Today | [Source Link](https://news.google.com/rss/articles/CBMi0AFBVV95cUxNWkoyY3hpbEJSUGhURk9DWXltSk5zSi1zbURHMmpyT0liUEEwRjZvRUtYZUQ2MUtlZUpQWTgyNE9pTktfcWxpT2VuRUtTSlRqNGpfXzdEdUdBMzZhRnJDREJTcVZIdENoVFZTUkMtVm93UnhIa205SHg0M1BXQkdRUUp6X1luOWlzeWJmSDU4NTQ3NC1jVV90cV9zTHpET1hVM2lQRVRWV2JadnNxZVVTTnJaaEkwZG1WVU1paEF0R1JNV0Z5cTg1bFoyZFR2cDJj?oc=5) |
| South Florida Times | Kidney drugs linked to longer survival even after age 80 | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxOVjFPb0MwRWRDbHlLT3hjR3FwdWRsTkktYXUtdUVlVERIeUtqZ1BBbEFZTUVqOGl4bDdyUDdXdzFJQlpxX0Y5NTA2NmFRSFRfMlhqYmtySXdiaTQxMEpaMkdyb0pJVUJkU2JSNGJsWnk5ZDVaMzlMQkt4Y1h3anhLOVlELUNaSERkbkdwdXdFekJhdw?oc=5) |
| Medical Xpress | ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxNMGJrVXpkZmZqajEtSFE2bUNob290dVBHaGFoUDY5RHVMM0dIc2NhZWt3NHNPUlJVV3VTVHhuanJhNS1KOS1wdHkwVG1fNGtXQlZQNncxUDkxbm5OVzhyU2pWdlZzVmZiVFBSTmRpcWhHbUE0UTNvVnpaSkc3S0ROSTFrdmI?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-11-03/asn-elderly-with-chronic-kidney-disease-benefit-from-sglt2-inhibitors*